Ignite Creation Date:
2024-05-06 @ 11:04 AM
Last Modification Date:
2024-10-26 @ 12:39 PM
Study NCT ID:
NCT03425643
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-11-13
First Post:
2018-02-02
Brief Title:
Efficacy and Safety of Pembrolizumab MK-3475 With Platinum Doublet Chemotherapy as NeoadjuvantAdjuvant Therapy for Participants With Resectable Stage II IIIA and Resectable IIIB T3-4N2 Non-small Cell Lung Cancer MK-3475-671KEYNOTE-671
Sponsor:
Organization:
Merck Sharp Dohme LLC
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
797
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: